ChemicalBook >> journal list >> Microbiology spectrum >>article
Microbiology spectrum

Microbiology spectrum

IF: 3.7
Download PDF

Evaluating the health risk of probiotic supplements from the perspective of antimicrobial resistance

Published:10 December 2024 DOI: 10.1128/spectrum.00019-24 PMID: 39655960
Qiwen Tian, Hailv Ye, Xuan Zhou, Junyi Wang, Lifang Zhang, Wenxuan Sun, Chenxin Duan, Minyu Fan, Wei Zhou, Chuyun Bi, Qiong Ye, Aloysius Wong

Abstract

Antimicrobial resistance remains a public health threat. Probiotics harboring antimicrobial resistant genes (ARGs) have, in recent years, been considered a potential health risk. Studies conducted on probiotics from increasingly popular health supplements have raised the possibility of transmitting ARGs to commensals in the human gut, concomitantly establishing a reservoir of ARGs and risking acquisition by opportunistic pathogens. Building on our previous study that reported multiple antibiotic resistance in probiotics of health supplements, in this research, we have attempted to detect their ARGs that may account for resistant phenotypes. ARGs responsible for tetracycline, macrolide, aminoglycoside, and glycopeptide resistance were prevalent in probiotics. Through laboratory adaptive evolution studies, we also show that streptomycin-adapted probiotics gained resistance to erythromycin, tetracycline, and doxycycline more effectively than non-adapted ones. When co-incubated with Enterococcus faecalis, Escherichia coli, or Staphylococcus aureus on Caco-2 and/or HCT-116 cells, streptomycin resistance was transferred from the adapted probiotics to generate transconjugants at frequencies comparable to or higher than that of other studies conducted through filter mating. Consistently, ARGs conferring resistance to streptomycin (aadA) and erythromycin [erm(B)-1] were detected in E. coli and S. aureus transconjugants, respectively, after co-incubation with streptomycin-adapted probiotics on Caco-2 cells. aadA and erm(B)-1 were both detected in E. faecalis transconjugant after the same co-incubation on HCT-116 cells. Our data and future comparative genomics and metagenomics studies conducted on animal models and in healthy, immunocompromised, and/or antibiotic-treated human cohorts will contribute to a more comprehensive understanding of probiotic consumption, application, and safety.

Importance: Probiotics are becoming increasingly popular, with promising applications in food and medicine, but the risk of transferring ARGs to disease-causing bacteria has raised concerns. Our study detected ARGs in probiotics of health supplements conferring resistance to tetracycline, macrolide, aminoglycoside, and glycopeptide drugs. Streptomycin-adapted probiotics also gained resistance to other antibiotics more effectively than non-adapted ones. Importantly, we showed that streptomycin resistance could be transferred to other bacteria after co-incubation with probiotics on human intestinal cells. ARGs responsible for erythromycin and streptomycin resistance, which were initially absent in the recipient bacteria, were also detected in the transconjugants. Our data build the foundation for future studies that will be conducted on animal models and in humans and leveraging advanced metagenomics approaches to clarify the long-term health risk of probiotic consumption.

Substances (6)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Erythromycin 114-07-8 C37H67NO13 957 suppliers $5.00-$2245.70
Streptomycin sulfate 3810-74-0 C21H41N7O16S 783 suppliers $15.00-$1880.00
Doxycycline hyclate 24390-14-5 C24H31ClN2O9 759 suppliers $17.47-$1700.00
Tetracycline hydrochloride 64-75-5 C22H25ClN2O8 699 suppliers $22.40-$2360.94
Amoxicillin trihydrate 61336-70-7 C16H21N3O6S 667 suppliers $10.00-$530.00
Piperacillin sodium salt 59703-84-3 C23H26N5NaO7S 376 suppliers $5.00-$654.00

Similar articles

IF:3

Study on the health risk of cyanuric acid in swimming pool water and its prevention and control measures

Frontiers in Public Health Zhe Chen, Yi Su,etc Published: 8 January 2024
IF:2.9

Creatine: are the benefits worth the risk?

Toxicology letters Mark A. Brudnak,etc Published: 15 April 2004